In addition to the PI3K-AKT pathway being a viable target for treating MM, previous MM treatments such as bortezomib, a proteosomal inhibitor, has been shown to induce MM apoptosis coinciding with increased FOXO3 expression and activity (141). Here, AKT1 is linked to Miyoshi myopathy.